Eptifibatide, Purity : 98%min.

Product name eptifibatide;?
sequence? mpr-har-gly-asp-trp-pro-cys-nh2
cas no. 148031-34-9
molecular formula c35h49n11o9s2
molecular weight 832.4
appearance white slightly yellwish powder
specific rotation[20d] -75.0～-95.0°（c=1，1%hac） ?
amino acids composition ± 10%
peptide purity (by hplc) ≥98% by area integration
related substance (by hplc) total impurities (%)≤2.0%? largest single impurity (%)≤ 1.0%
water content (karl fischer) ≤8.0%
peptide content(n determination) ≥80%
acetate content ≤15%
ir spectrum in accordance
brief introduction:
eptifibatide (integrilin, millennium pharmaceuticals, also co-promoted by schering-ploughessex), is an antiplatelet drug of the glycoprotein iibiiia inhibitor class.[1] eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (sistrurus miliarius barbouri).
it belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of gpiibiiia that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
indications
eptifibatide is used to reduce the risk of acute cardiac ischemic events (death andor myocardial infarction) in patients with unstable angina or non-st-segment-elevation (e.g., non-q-wave) myocardial infarction (i.e., non-st-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (pci).